Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Featured trial
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

The primary objective of this study is:To evaluate the efficacy of fostamatinib when used in combination with standard of care (SOC) in subjects hospitalized with

covid-19
  • 2 views
  • 10 Dec, 2021
  • 35 locations
Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa

A 16 week exploratory, Proof of Concept study to evaluate the effect of Fostamatinib (12 weeks of treatment) upon cutaneous inflammation in Hidradenitis Suppurativa.

  • 0 views
  • 27 Apr, 2022
  • 1 location
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

This research is being done to test the safety of the combination of the study drugs fostamatinib and paclitaxel. This study tests different doses of the drugs to see which doses are safest in

paclitaxel
cancer of the ovary
fallopian tube
primary peritoneal carcinoma
peritoneal carcinoma
  • 15 views
  • 27 Feb, 2022
  • 1 location
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Fostamatinib may improve thrombocytopenia in myelofibrosis patients with severe thrombocytopenia (platelet <50,000/microL) and allow them to initiate treatment with a JAK2 inhibitor

  • 0 views
  • 25 May, 2022
  • 1 location
Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

This phase I trial is to find out the best dose, possible benefits and/or side effects of fostamatinib in treating patients with lower-risk myelodysplastic syndromes or chronic myelomonocytic

  • 0 views
  • 12 Sep, 2021
  • 1 location
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult

fostamatinib
immune globulin
thrombocytopenia
immunoglobulins
  • 0 views
  • 28 Jul, 2021
  • 8 locations